RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RHK - DE0007042301 - Common Stock
12.7 EUR
-0.3 (-2.31%)
Taking everything into account, RHK scores 4 out of 10 in our fundamental rating. RHK was compared to 28 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for RHK as it has an excellent financial health rating, but there are worries on the profitability. RHK is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RHK had positive earnings in the past year.
In the past year RHK had a positive cash flow from operations.
RHK had positive earnings in each of the past 5 years.
In the past 5 years RHK always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of 2.02%, RHK is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
With a Return On Equity value of 2.90%, RHK is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
RHK has a Return On Invested Capital of 2.67%. This is in the lower half of the industry: RHK underperforms 75.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 6.91%.
The last Return On Invested Capital (2.67%) for RHK is above the 3 year average (2.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROIC | 2.67% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
RHK's Profit Margin of 2.28% is on the low side compared to the rest of the industry. RHK is outperformed by 64.29% of its industry peers.
In the last couple of years the Profit Margin of RHK has declined.
RHK has a worse Operating Margin (2.86%) than 71.43% of its industry peers.
RHK's Operating Margin has declined in the last couple of years.
RHK has a Gross Margin of 66.81%. This is in the better half of the industry: RHK outperforms 75.00% of its industry peers.
In the last couple of years the Gross Margin of RHK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RHK is destroying value.
Compared to 1 year ago, RHK has about the same amount of shares outstanding.
RHK has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for RHK has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.07 indicates that RHK is not in any danger for bankruptcy at the moment.
The Altman-Z score of RHK (3.07) is better than 78.57% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
The Debt to Equity ratio of RHK (0.09) is better than 92.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.07 |
ROIC/WACC0.41
WACC6.48%
2.3 Liquidity
RHK has a Current Ratio of 2.28. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
RHK has a better Current ratio (2.28) than 92.86% of its industry peers.
A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
RHK has a Quick ratio of 2.19. This is amongst the best in the industry. RHK outperforms 92.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 |
3. Growth
3.1 Past
The earnings per share for RHK have decreased strongly by -15.41% in the last year.
Measured over the past 5 years, RHK shows a small growth in Earnings Per Share. The EPS has been growing by 0.03% on average per year.
The Revenue has grown by 9.10% in the past year. This is quite good.
Measured over the past years, RHK shows a small growth in Revenue. The Revenue has been growing by 4.12% on average per year.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
3.2 Future
Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.89% on average per year.
The Revenue is expected to grow by 6.24% on average over the next years.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 22.28 indicates a rather expensive valuation of RHK.
Based on the Price/Earnings ratio, RHK is valued a bit more expensive than 64.29% of the companies in the same industry.
RHK's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.77.
A Price/Forward Earnings ratio of 16.62 indicates a correct valuation of RHK.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RHK is on the same level as its industry peers.
RHK is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.28 | ||
| Fwd PE | 16.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.39 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)5.18
PEG (5Y)655.19
EPS Next 2Y10.47%
EPS Next 3Y11.09%
5. Dividend
5.1 Amount
RHK has a yearly dividend return of 0.77%, which is pretty low.
Compared to an average industry Dividend Yield of 1.47, RHK has a dividend in line with its industry peers.
With a Dividend Yield of 0.77, RHK pays less dividend than the S&P500 average, which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.77% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
RHK pays out 17.78% of its income as dividend. This is a sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
FRA:RHK (12/30/2025, 7:00:00 PM)
12.7
-0.3 (-2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap850.39M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (13.78%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.77% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.43%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.28 | ||
| Fwd PE | 16.62 | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | 13.78 | ||
| P/B | 0.65 | ||
| P/tB | 0.76 | ||
| EV/EBITDA | 0.39 |
EPS(TTM)0.57
EY4.49%
EPS(NY)0.76
Fwd EY6.02%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.26%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.18
PEG (5Y)655.19
Graham Number15.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROCE | 3.25% | ||
| ROIC | 2.67% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 5.55% | ||
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% | ||
| FCFM | N/A |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.07 | ||
| Cap/Depr | 112.99% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 14.78 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 | ||
| Altman-Z | 3.07 |
F-Score6
WACC6.48%
ROIC/WACC0.41
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y28.34%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%
RHOEN-KLINIKUM AG / RHK.DE FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 4 / 10 to RHK.DE.
What is the valuation status for RHK stock?
ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
What is the profitability of RHK stock?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 3 / 10.
What is the valuation of RHOEN-KLINIKUM AG based on its PE and PB ratios?
The Price/Earnings (PE) ratio for RHOEN-KLINIKUM AG (RHK.DE) is 22.28 and the Price/Book (PB) ratio is 0.65.
Can you provide the expected EPS growth for RHK stock?
The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 4.3% in the next year.